CTOs on the Move

Aastrom

www.aastrom.com

 
We are committed to helping people with severe, chronic cardiovascular diseases realize the promise of patient-specific, expanded multicellular therapy.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.aastrom.com
  • 24 Frank Lloyd Wright Drive
    Ann Arbor, MI USA 48105
  • Phone: 734.418.4400

Executives

Name Title Contact Details

Similar Companies

ADF Engineering Inc

ADF Engineering Inc is a Miamisburg, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Children's Hospital Oakland Research Institute

Children's Hospital Oakland Research Institute is a Oakland, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

5 PRIME

5 PRIME is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Trident Health System

Trident Health is the leading provider of laboratory and mobile imaging services to the long term care community in the US. Operating in 43 states, we currently provide these services to more than 5,000 of the 16,000+ long term care facilities in the US.

Allogene

Allogene Therapeutics is a biotechnology company with a mission to catalyze the next revolution in cancer treatment through the development of allogeneic chimeric antigen receptor T-cell (CAR T) therapy directed at blood cancers and solid tumors. Founded and led by former Kite Pharma executives who bring unrivaled clinical development acumen in cell therapy, Allogene is well-positioned to further the potential of allogeneic cell therapy for patients. Allogeneic CAR T therapies are engineered from cells of healthy donors and stored for “off-the-shelf” use in patients. This approach eliminates the need to create personalized therapy from a patient`s own cells, simplifies manufacturing, and reduces the time patients must wait for CAR T treatment. The Allogene portfolio includes 16 pre-clinical T cell therapy assets and UCART19, an allogeneic CAR T therapy currently in Phase 1 development for the treatment of acute lymphoblastic leukemia (ALL). Through its notable partnerships, Allogene leverages pioneering technology platforms, including TALEN® gene editing technology, to progress its portfolio of immuno-oncology therapies. Allogene, with headquarters in San Francisco, California, is a Two River portfolio company formed with one of the largest Series A financings in biotechnology from an investment consortium that includes TPG, Vida Ventures, BellCo Capital, the University of California Office of the Chief Investment Officer and Pfizer, among others.